2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. Ephrin Receptor
  5. Ephrin Receptor Antagonist

Ephrin Receptor Antagonist

Ephrin Receptor Isoform Comparison

Ephrin Receptor Antagonists (8):

Cat. No. Product Name Effect Purity
  • HY-133178
    Urolithin D
    		Antagonist 99.72%
    Urolithin D is competitive and reversible antagonist of EphA receptors. Urolithin D exhibits intra-classes selectivity.
  • HY-133178R
    Urolithin D (Standard)
    		Antagonist
    Azathramycin (Standard) is the analytical standard of Azathramycin. This product is intended for research and analytical applications. Azathramycin (Azaerythromycin A) is an antibiotic that targets ribosomes and possesses antibacterial activity, which can be used in research related to infectious diseases.
  • HY-123607
    UniPR129
    		Antagonist 99.23%
    UniPR129 is a potent Eph/ephrin antagonist with IC50s of 0.84-3.01 μM. UniPR129 has the potential for the research of cancer disease.
  • HY-157019
    UniPR1447
    		Antagonist 99.46%
    UniPR1447 is Dual EphA2 and EphB2 antagonist, with an IC50 of 6.6 μM for EphA2−ephrin-A1 binding.
  • HY-146375
    UniPR505
    		Antagonist
    UniPR505 (Compound 14) is an EphA2 antagonist with an IC50 of 0.95 µM. UniPR505 displays anti-angiogenic properties.
  • HY-157020
    UniPR1449
    		Antagonist
    UniPR1449 is an antagonist of EphA2 receptor, with th KD of 3.8±2.4 μM, that plays an important role in cancer.
  • HY-163835
    UniPR1454
    		Antagonist
    UniPR1454 targets EphA2 receptor, inhibits the EphA2-ephrin A1 interaction with an IC50 of 2.6 μM. UniPR1454 inhibits the proliferation of glioblastoma cell U251.
  • HY-171175
    UniPR500
    		Antagonist
    UniPR500, a UniPR129 derivative, is a competitive EphA2 receptor antagonist with a Ki of 0.78 μM. UniPR500 dose-dependently reduces binding of biotinylated ephrin-A1 to EphA2 with an IC50 value of 1.1 μM.